Dr. Mikhael’s predominant research interest is in multiple myeloma and its related conditions: Waldenstrom’s macroglobulinemia and amyloidosis. He also does research in medical education, benign hematology and pharmacoeconomics:
- Multiple myeloma, Waldenstrom’s and amyloidosis: He is the principal investigator of multiple clinical trials in both newly diagnosed and relapsed disease. He is also interested in the field of quality-of-life in multiple myeloma patients.
- Medical education: Dr Mikhael is interested in various innovative methods of medical education.
- Benign hematology: He is involved in research in agents for thrombosis. He also is involved in ITP research.
- Pharmacoeconomics: He develops models to account for the cost of cancer care and validates therapies based upon their cost-effectiveness.
The use of social media to reach out to patients and help improve clinical trials
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
The Phase II clinical trial of ixazumib, the first oral proteasome inhibitor in MM